Aurinia Pharmaceuticals Inc (AUPH) News
Filter AUPH News Items
AUPH News Results
|Event/Time||Symbol||Company||News Detail||Start||End||Change||POWR Rating|
|Loading, please wait...|
Latest AUPH News From Around the Web
Below are the latest news stories about Aurinia Pharmaceuticals Inc that investors may wish to consider to help them evaluate AUPH as an investment opportunity.
Aurinia Completes Final Patient Treatment in AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eye Syndrome
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (Aurinia or the Company), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple autoimmune conditions, today announced that the last patient study visit has occurred in the Phase 2/3 AUDREY™ clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES). “Despite the challenges posed by the ongoing vi
The following slide deck was published by Aurinia Pharmaceuticals Inc. in conjunction with this event....
VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that the Company’s Compensation Committee granted 105 new employees non-qualified stock options to purchase an aggregate of 530,000 common shares, at a per share exercise price of $14.83 USD, the closing trading price on August 31,
Aurinia Pharmaceuticals, Inc.'s (AUPH) CEO Peter Greenleaf on Q2 2020 Results - Earnings Call Transcript
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2020 Results Earnings Conference Call August 11, 2020, 04:30 PM ET Company Participants Glenn Schulman - SVP, Corporate Communications and IR Peter Greenleaf - CEO and Director Neil Solomons - Chief Medical Officer Max Colao - Chief Commercial Officer Joe Miller - Chief Financial Officer...
Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) were unchanged after-market trading after the company reported Q2 results. Quarterly Results Earnings …
This article was highlighted for PRO subscribers, Seeking Alpha’s service for professional investors. Find out how you can get the best content on Seeking Alpha here. Aurinia Pharmaceuticals (AUPH) is a Canadian drug company which has recently received expedited FDA review for its lupus nephritis ("LN") treatment Voclosporin. The company...
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its second quarter 2020 financial results on Tuesday, August 11, 2020, after the markets close. Aurinia’s executive team will host a conference call to discuss the Company’s financial results and to provide a general business update. The conference call and webcast is scheduled for 4:30 pm EDT on August 11, 2020. In order to participate in the
Aurinia Pharmaceuticals Inc. Completes US$200 Million Public Offering Of Common Shares - Corporate/Commercial Law - Canada
On July 27, 2020, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (Aurinia or the Company) closed its underwritten public offering of 13,333,334 common shares (the Offering).
Aurinia Pharmaceuticals (AUPH) has priced its public offering of ~13.3M common shares at $15.00/share, for gross proceeds of ~$200M. Underwriters' over-allotment is an additional 2M shares. Net proceeds will be used for pre-commercialization and launch activities, R&D as well as working capital and general corporate purposes.Closing date is July 27.Previously:...
One day after moving higher in the market, Aurinia Pharmaceuticals (NASDAQ: AUPH) stock was deep in the loss column on Thursday. Optimism flowing from good news the previous day was erased by the Canadian biotech's announcement that it's floating a new, $200 million secondary stock issue consisting of slightly over 13.3 million common shares. Aurinia's motives for this fresh round of capital-raising seem pure.